title: Evaluation of cardiac sympathetic nervous function by 123I-metaiodobenzylguanidine scintigraphy in insulin-treated non-insulin dependent diabetics with hypoglycemia unawareness.
abstract: The association between the lack of adrenergic symptoms during hypoglycemia and myocardial 123I-metaiodobenzylguanidine (MIBG) accumulation was investigated in 12 insulin-treated non-insulin-dependent diabetes mellitus (NIDDM) patients who had no evidence of heart disease. These patients were divided into 2 groups according to the presence (group A) or absence (group B) of adrenergic symptoms during hypoglycemia. Autonomic function tests revealed significantly severe autonomic dysfunction in group B compared to that in group A. Insulin infusion test indicated no significant difference in the catecholamine response between the two groups. 123I-MIBG scintigraphy showed that the heart/mediastinum ratio of MIBG uptake was significantly lower, and scintigraphic defect was greater in group B than in group A. There were no significant differences in the washout rate between the two groups. These results suggested that the lack of adrenergic symptoms during hypoglycemia may be associated with cardiac sympathetic nervous dysfunction in insulin-treated NIDDM patients, and this dysfunction is mainly due to cardiac sympathetic denervation.
authors.affiliation: Gunma Prefectural Cardiovascular Center, Maebashi.
authors.forename: T
authors.initials: T
authors.lastname: Ohno
authors.forename: T
authors.initials: T
authors.lastname: Toyama
authors.forename: H
authors.initials: H
authors.lastname: Hoshizaki
authors.forename: E
authors.initials: E
authors.lastname: Okamoto
authors.forename: S
authors.initials: S
authors.lastname: Naito
authors.forename: A
authors.initials: A
authors.lastname: Nogami
authors.forename: H
authors.initials: H
authors.lastname: Kamiyama
authors.forename: S
authors.initials: S
authors.lastname: Ohshima
authors.forename: K
authors.initials: K
authors.lastname: Yuasa
authors.forename: K
authors.initials: K
authors.lastname: Taniguchi
authors.forename: S
authors.initials: S
authors.lastname: Tomono
authors.forename: S
authors.initials: S
authors.lastname: Kawazu
mesh_terms: D019797:3-Iodobenzylguanidine; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D004837:Epinephrine / Q000097:blood; D006321:Heart / Q000000981:diagnostic imaging / Q000294:innervation*; D006334:Heart Function Tests; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010465:Perception; D011877:Radionuclide Imaging; D013564:Sympathetic Nervous System / Q000000981:diagnostic imaging / Q000503:physiopathology*; D013565:Sympatholytics
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D013565:Sympatholytics; D019797:3-Iodobenzylguanidine; D009638:Norepinephrine; D004837:Epinephrine